Document Detail

Angioscopic evaluation of stabilizing effects of an antilipemic agent, bezafibrate, on coronary plaques in patients with coronary artery disease: a multicenter prospective study.
MedLine Citation:
PMID:  12227708     Owner:  NLM     Status:  MEDLINE    
To evaluate the stabilizing effects of an antilipemic agent, bezafibrate, on coronary plaques, we carried out a prospective angioscopic and angiographic open trial. From April 1997 to December 1998, 24 patients underwent coronary angioscopy of plaques in non-targeted vessels during coronary interventions and then again 6 months later. The patients were divided into control (10 patients, 14 plaques) and bezafibrate (14 patients, 21 plaques) groups. Oral administration of bezafibrate (400 mg/day) was started immediately after the intervention and was continued for 6 months. The vulnerability score was determined based on the angioscopic characteristics of plaques and compared before and 6 months later. Six months later, the vulnerability score was reduced (from 1.6 to 0.8; P<0.05) in the bezafibrate group and unchanged (from 1.4 to 1.3; NS) in the control group. In the bezafibrate group, the changes in the vulnerability score were not correlated with those in % stenosis or minimal lumen diameter. The plasma total cholesterol level (T-C) was unchanged, triglyceride level (TG) was decreased, and high density lipoprotein cholesterol level (HDL-C) was increased in the bezafibrate group, but were unchanged in the control group. In the bezafibrate group, T-C and TG were decreased and HDL-C was increased in patients with a reduced vulnerability score but were unchanged in those with an unchanged score. These results indicate that 6 month administration of bezafibrate stabilizes coronary plaques and that the stabilization is not correlated with angiographic changes.
Hidefumi Ohsawa; Yasumi Uchida; Yoshiharu Fujimori; Junichi Hirose; Hirofumi Noike; Keiichi Tokuhiro; Kohei Kawamura; Masahito Kanai; Hiroshi Sakuragawa; Takashi Hitsumoto; Kaneyuki Aoyagi; Takeshi Sakurai; Shin Sato; Kunio Yoshinaga; Michihisa Kaku; Masaaki Ozegawa; Hiroshi Morio; Katsumi Yamada; Kimiko Terasawa; Yuuko Uchida; Tomomitsu Ohshima
Related Documents :
9869668 - Effect of hmg-coa reductase inhibitors on coronary artery disease as assessed by electr...
17239888 - Comparative effects on lipid levels of combination therapy with a statin and extended-r...
22677638 - "triple-ten" in the treatment of acute ocular complications from toxic epidermal necrol...
10661618 - The long-term tolerability and efficacy of oesclim: results of a 1-year study.
20620788 - Hamstring donor-site block: evaluation of pain control after anterior cruciate ligament...
18291158 - Incidence, topography, predictors and long-term survival after stroke in patients under...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article; Multicenter Study    
Journal Detail:
Title:  Japanese heart journal     Volume:  43     ISSN:  0021-4868     ISO Abbreviation:  Jpn Heart J     Publication Date:  2002 Jul 
Date Detail:
Created Date:  2002-09-13     Completed Date:  2002-10-03     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0401175     Medline TA:  Jpn Heart J     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  319-31     Citation Subset:  IM    
Cardiovascular Center, Sakura Hospital of Toho University School of Medicine, Narita Red Cross Hospital, Chiba, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antilipemic Agents / therapeutic use*
Bezafibrate / therapeutic use*
Cholesterol / blood
Cholesterol, HDL / blood
Coronary Angiography
Coronary Disease / drug therapy*
Middle Aged
Prospective Studies
Reg. No./Substance:
0/Antilipemic Agents; 0/Cholesterol, HDL; 0/Triglycerides; 41859-67-0/Bezafibrate; 57-88-5/Cholesterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  New protocol to detect coronary spastic angina without fixed stenosis.
Next Document:  Effects of anti-vasospastic agents in Japanese patients with dilated cardiomyopathy and coronary vas...